Synthesis and Preclinical Evaluation of [ 18 F]AlF‐NOTA‐Asp 2 ‐PEG 2 ‐Folate as a Novel Folate‐Receptor‐Targeted Tracer for PET Imaging
Journal of Labelled Compounds and Radiopharmaceuticals · 2024
DOI: 10.1002/jlcr.4118 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, 2024. Verfasst von Haoran Liang und 3 weiteren Autor:innen. Beteiligte Einrichtung: GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, PET Center and Department of Nuclear Medicine, Nanfang Hospital, Sou…. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Fluorine Radioisotopes, Folic Acid. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Recently, the folate receptor (FR) has become an exciting target for the diagnosis of FR‐positive malignancies. Nevertheless, suboptimal in vivo pharmacokinetic properties, particularly high uptake in the renal and hepatobiliary systems, are important limiting factors for the clinical translation of most FR‐based radiotracers. In this study, we developed a novel 18 F‐labeled FR‐targeted positron emission tomography (PET) tracer [ 18 F]AlF‐NOTA‐Asp 2 ‐PEG 2 ‐Folate modified with a hydrophilic linker (−Asp 2 ‐PEG 2 ) to optimize its pharmacokinetic properties and conducted a comprehensive preclinical assessment. The [ 18 F]AlF‐NOTA‐Asp 2 ‐PEG 2 ‐Folate was manually synthesized within 30 min with a non‐decay‐corrected radiochemical yield of 16.3 ± 2.0% ( n = 5). Among KB cells, [ 18 F]AlF‐NOTA‐Asp 2 ‐PEG 2 ‐Folate exhibited high specificity and affinity for FR. PET/CT imaging and biodistribution experiments in KB tumor‐bearing mice showed decent tumor uptake (1.7 ± 0.3% ID/g) and significantly decreased uptake in kidneys and liver (22.2 ± 2.1 and 0.3 ± 0.1% ID/g at 60 min p.i., respectively) of [ 18 F]AlF‐NOTA‐Asp 2 ‐PEG 2 ‐Folate, compared to the known tracer [ 18 F]AlF‐NOTA‐Folate (78.6 ± 5.1 and 5.3 ± 0.5 % ID/g at 90 min p.i., respectively). The favorable properties of [ 18 F]AlF‐NOTA‐Asp 2 ‐PEG 2 ‐Folate, including its efficient synthesis, decent tumor uptake, relatively low renal uptake, and rapid clearance from most normal organs, portray it as a promising PET tracer for FR‐positive tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, PET Center and Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
- School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
ORCID-Profile: Haoran Liang
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Guangzhou Science and Technology Plan
- Medical Products Administration of Guangdong Province
- Nanfang Hospital Talent Introduction Foundation of Southern Medical University
- Guangzhou Municipal Science and Technology Project
Zitieren
APA
Liang, H., Chen, Z., Mo, C., & Tang, G. (2024). Synthesis and Preclinical Evaluation of [ 18 F]AlF‐NOTA‐Asp 2 ‐PEG 2 ‐Folate as a Novel Folate‐Receptor‐Targeted Tracer for PET Imaging. Journal of Labelled Compounds and Radiopharmaceuticals. https://doi.org/10.1002/jlcr.4118
Vancouver
Liang H, Chen Z, Mo C, Tang G. Synthesis and Preclinical Evaluation of [ 18 F]AlF‐NOTA‐Asp 2 ‐PEG 2 ‐Folate as a Novel Folate‐Receptor‐Targeted Tracer for PET Imaging. Journal of Labelled Compounds and Radiopharmaceuticals. 2024. doi:10.1002/jlcr.4118
BibTeX
@article{Liang2024,
author = {Liang, Haoran and Chen, Zihao and Mo, Chunwei and Tang, Ganghua},
title = {Synthesis and Preclinical Evaluation of [ 18 F]AlF‐NOTA‐Asp 2 ‐PEG 2 ‐Folate as a Novel Folate‐Receptor‐Targeted Tracer for PET Imaging},
journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
year = {2024},
doi = {10.1002/jlcr.4118}
}
EUVIMED